

Ordered Items: **CMP14+CBC/D/Plt+Mg+TSH+Fer+...; NMR LipoProfile+Lipids+Graph; Dihydrotestosterone; Drawing Fee**

Date Collected: 08/21/2021	Date Received: 08/21/2021	Date Reported: 08/26/2021	Fasting: Yes
----------------------------	---------------------------	---------------------------	--------------

CMP14+CBC/D/Plt+Mg+TSH+Fer+...

Test	Current Result and Flag	Previous Result and Date		Units	Reference Interval
Glucose ⁰¹	95	97	11/05/2020	mg/dL	65-99
Hemoglobin A1c ⁰¹	5.3	5.1	11/05/2020	%	4.8-5.6
Please Note: ⁰¹					
Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0					
BUN ⁰¹	10	10	11/05/2020	mg/dL	6-20
Creatinine ⁰¹	0.76	0.75	11/05/2020	mg/dL	0.57-1.00
eGFR If NonAfricn Am	104	107	11/05/2020	mL/min/1.73	>59
eGFR If Africn Am	120	123	11/05/2020	mL/min/1.73	>59
Labcorp currently reports eGFR in compliance with the current recommendations of the National Kidney Foundation. Labcorp will update reporting as new guidelines are published from the NKF-ASN Task force.					
BUN/Creatinine Ratio	13	13	11/05/2020		9-23
Sodium ⁰¹	140	140	11/05/2020	mmol/L	134-144
Potassium ⁰¹	4.2	3.9	11/05/2020	mmol/L	3.5-5.2
Chloride ⁰¹	105	104	11/05/2020	mmol/L	96-106
Carbon Dioxide, Total ⁰¹	24	22	11/05/2020	mmol/L	20-29
Calcium ⁰¹	9.4	9.2	11/05/2020	mg/dL	8.7-10.2
Magnesium ⁰¹	2.1	2.1	11/05/2020	mg/dL	1.6-2.3
Protein, Total ⁰¹	6.7	6.7	11/05/2020	g/dL	6.0-8.5
Albumin ⁰¹	4.6	4.5	11/05/2020	g/dL	3.8-4.8
Globulin, Total	2.1	2.2	11/05/2020	g/dL	1.5-4.5
A/G Ratio	2.2	2.0	11/05/2020		1.2-2.2
Bilirubin, Total ⁰¹	0.6	0.3	11/05/2020	mg/dL	0.0-1.2
Alkaline Phosphatase ⁰¹	48	41*	11/05/2020	IU/L	48-121
AST (SGOT) ⁰¹	22	22	11/05/2020	IU/L	0-40
ALT (SGPT) ⁰¹	29	20	11/05/2020	IU/L	0-32
Ferritin, Serum ⁰¹	71	92	11/05/2020	ng/mL	15-150

CMP14+CBC/D/Plt+Mg+TSH+Fer+... (Cont.)

Vitamin B12 ⁰¹	1228	1701	11/05/2020	pg/mL	232-1245
Folate, Hemolysate ⁰¹	539.0	554.0	11/05/2020	ng/mL	Not Estab.
Folate, RBC	1253	1322	11/05/2020	ng/mL	>498
Vitamin D, 25-Hydroxy ⁰¹	43.9	58.0	11/05/2020	ng/mL	30.0-100.0

Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).

1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.

C-Reactive Protein, Cardiac ⁰¹	0.56	0.62	11/05/2020	mg/L	0.00-3.00
---	------	------	------------	------	-----------

Relative Risk for Future Cardiovascular Event

Low	<1.00
Average	1.00 - 3.00
High	>3.00

Homocyst(e)ine ⁰¹	5.8	6.5	11/05/2020	umol/L	0.0-14.5
▲ Coenzyme Q10, Total ^{A, 01}	3.00	High	2.09	11/05/2020	ug/mL 0.37-2.20
TSH ⁰¹	1.530	2.02	11/05/2020	uIU/mL	0.450-4.500
Triiodothyronine (T3), Free ⁰¹	2.8	3.5	11/05/2020	pg/mL	2.0-4.4
T4,Free(Direct) ⁰¹	1.44	1.44	11/05/2020	ng/dL	0.82-1.77
Thyroid Peroxidase (TPO) Ab ⁰¹	<8	<9*	11/05/2020	IU/mL	0-34
Thyroglobulin Antibody ⁰¹	<1.0	<1.0*	11/05/2020	IU/mL	0.0-0.9

Thyroglobulin Antibody measured by Beckman Coulter Methodology

Cortisol ⁰¹	10.5			ug/dL	
------------------------	------	--	--	-------	--

Cortisol AM	6.2 - 19.4
Cortisol PM	2.3 - 11.9

Insulin-Like Growth Factor I ⁰¹	191	178	11/05/2020	ng/mL	84-281
--	-----	-----	------------	-------	--------

CMP14+CBC/D/Plt+Mg+TSH+Fer+... (Cont.)

LH ⁰¹	9.3	8.3	11/05/2020	mIU/mL	
<div>Adult Female:</div> <div>Follicular phase2.4 - 12.6</div> <div>Ovulation phase14.0 - 95.6</div> <div>Luteal phase1.0 - 11.4</div> <div>Postmenopausal7.7 - 58.5</div>					
FSH ⁰¹	6.3	9.2	11/05/2020	mIU/mL	
<div>Adult Female:</div> <div>Follicular phase3.5 - 12.5</div> <div>Ovulation phase4.7 - 21.5</div> <div>Luteal phase1.7 - 7.7</div> <div>Postmenopausal25.8 - 134.8</div>					
▲ Prolactin ⁰¹	25.7	High	24.0	11/05/2020	ng/mL4.8-23.3
Sex Horm Binding Glob, Serum ⁰¹	37.4		56.0	11/05/2020	nmol/L24.6-122.0
Insulin ⁰¹	10.8		10.1	11/05/2020	uIU/mL2.6-24.9
Fibrinogen Activity ⁰¹	305		325	11/05/2020	mg/dL193-507
CBC, Platelet Ct, and Diff ⁰¹					
WBC ⁰¹	4.6		5.5	11/05/2020	x10E3/uL3.4-10.8
RBC ⁰¹	4.77		4.7	11/05/2020	x10E6/uL3.77-5.28
Hemoglobin ⁰¹	14.5		14.0	11/05/2020	g/dL11.1-15.9
Hematocrit ⁰¹	43.0		41.9	11/05/2020	%34.0-46.6
MCV ⁰¹	90		89	11/05/2020	fL79-97
MCH ⁰¹	30.4		29.8	11/05/2020	pg26.6-33.0
MCHC ⁰¹	33.7		33.4	11/05/2020	g/dL31.5-35.7
RDW ⁰¹	12.1		11.9	11/05/2020	%11.7-15.4
Platelets ⁰¹	160		168	11/05/2020	x10E3/uL150-450
Neutrophils ⁰¹	47		47	11/05/2020	%Not Estab.
Lymphs ⁰¹	41		42	11/05/2020	%Not Estab.
Monocytes ⁰¹	8		6	11/05/2020	%Not Estab.
Eos ⁰¹	3		4	11/05/2020	%Not Estab.
Basos ⁰¹	1		1	11/05/2020	%Not Estab.
Neutrophils (Absolute) ⁰¹	2.2		2.6	11/05/2020	x10E3/uL1.4-7.0
Lymphs (Absolute) ⁰¹	1.9		2.3	11/05/2020	x10E3/uL0.7-3.1
Monocytes(Absolute) ⁰¹	0.3		0.3	11/05/2020	x10E3/uL0.1-0.9
Eos (Absolute) ⁰¹	0.1		0.2	11/05/2020	x10E3/uL0.0-0.4

CMP14+CBC/D/Plt+Mg+TSH+Fer+... (Cont.)

Baso (Absolute) ⁰¹	0.0	0.0	11/05/2020	x10E3/uL	0.0-0.2
Immature Granulocytes ⁰¹	0	0	11/05/2020	%	Not Estab.
Immature Grans (Abs) ⁰¹	0.0	0.0	11/05/2020	x10E3/uL	0.0-0.1

* Previous Reference Intervals: (Alkaline Phosphatase: 39-117 IU/L IU/L), (Thyroid Peroxidase (TPO) Ab: 0-34 IU/mL), (Thyroglobulin Antibody: 0.0-0.9 IU/mL)

NMR LipoProfile+Lipids+Graph

Test	Current Result and Flag		Previous Result and Date		Units	Reference Interval
LDL Particle Number ⁰¹						
▲ LDL-P ^{A, 01}	1754	High	1880	11/05/2020	nmol/L	<1000
						Low < 1000 Moderate 1000 - 1299 Borderline-High 1300 - 1599 High 1600 - 2000 Very High > 2000
Lipids ⁰¹						
▲ LDL-C (NIH Calc) ⁰¹	147	High	134	11/05/2020	mg/dL	0-99
						Optimal < 100 Above optimal 100 - 129 Borderline 130 - 159 High 160 - 189 Very high > 189
HDL-C ^{A, 01}	59		63	11/05/2020	mg/dL	>39
Triglycerides ^{A, 01}	115		98	11/05/2020	mg/dL	0-149
▲ Cholesterol, Total ^{A, 01}	226	High	214	11/05/2020	mg/dL	100-199
LDL and HDL Particles ⁰¹						
HDL-P (Total) ^{A, 01}	36.6		38.2	11/05/2020	umol/L	>=30.5
▲ Small LDL-P ^{A, 01}	540	High	620	11/05/2020	nmol/L	<=527
LDL Size ^{A, 01}	21.7		21.6	11/05/2020	nm	>20.5

** INTERPRETATIVE INFORMATION**					
PARTICLE CONCENTRATION AND SIZE					
<---Lower CVD Risk Higher CVD Risk-->					
LDL AND HDL PARTICLES	Percentile in	Reference Population			
HDL-P (total)	High	75th	50th	25th	Low
	>34.9	34.9	30.5	26.7	<26.7
Small LDL-P	Low	25th	50th	75th	High
	<117	117	527	839	>839

NMR LipoProfile+Lipids+Graph (Cont.)

LDL Size	<-Large (Pattern A)->	<-Small (Pattern B)->
	23.0 20.6	20.5 19.0

Comment: ⁰¹

Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

Insulin Resistance Score ⁰¹

▲ LP-IR Score ^{A, 01}	49	High	46	11/05/2020	<=45
--------------------------------	----	------	----	------------	------

INSULIN RESISTANCE MARKER
<--Insulin Sensitive Insulin Resistant-->
Percentile in Reference Population
Insulin Resistance Score
LP-IR Score Low 25th 50th 75th High
<27 27 45 63 >63

Comment: ⁰¹

LP-IR Score is inaccurate if patient is non-fasting.
The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.

PDF ⁰¹

11/05/2020

Dihydrotestosterone

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Dihydrotestosterone ⁰²	11	12 11/05/2020	ng/dL	

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
Reference Range:
Adult Female: 4 - 22

Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 3 years where there is sufficient patient demographic data to match the result to the patient.

Icon Legend

▲ Out of reference range ■ Critical or Alert

Patient ID:

Age: 32

Account Number: 10215230

Specimen ID: 233-174-1511-0

Sex: Female

Ordering Physician: L FLOWERS

Comments

A: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Performing Labs

01: BN - LabCorp Burlington 1447 York Court, Burlington, NC, 27215-3361 Dir: Sanjai Nagendra, MD

02: ES - Esoterix Inc 4301 Lost Hills Road, Calabasas Hills, CA, 91301-5358 Dir: Brian Poirier, MD

For Inquiries, the physician can contact Branch: 205-581-3500 Lab: 800-762-4344

Patient Details**Carver, Lindsey****2720 TRYON PINES DR, RALEIGH, NC, 27603**

Phone: 757-880-2206

Date of Birth: 03/26/1989

Age: 32

Sex: Female

Patient ID:

Alternate Patient ID:

Physician Details**L FLOWERS****Flowers Medical Group****1950 Spectrum Circle Suite 505, Marietta, GA, 30067**

Phone: 678-303-4420

Account Number: 10215230

Physician ID: 12731387

NPI: 1295088557

Specimen Details

Specimen ID: 233-174-1511-0

Control ID: B0116788491

Alternate Control Number: B0116788491

Date Collected: 08/21/2021 0923 Local

Date Received: 08/21/2021 0000 ET

Date Entered: 08/21/2021 1215 ET

Date Reported: 08/26/2021 1409 ET

Rte: 15

Specimen Number 233-174-1511-0		Patient ID		Account Number 10215230	Account Phone (678) 303-4420	Account Fax (678) 303-4420
Patient Last Name CARVER		Patient First Name LINDSEY		Account Address Flowers Medical Group Lynn Flowers MD 1950 Spectrum Circle Suite 505 Marietta, GA 30067		
Age 32	Date of Birth 03/26/1989	Sex F	Fasting YES			
Control Number B0116788491		NPI 1295088557				
Date Collected 08/21/2021	Date Entered 08/21/2021	Date and Time Reported 08/22/2021 06:15 PM ET		Physician ID & Name 12731387 - FLOWERS, L		Page Number 1 of 2

❖ **NMR LipoProfile® test**

Reference Interval¹

	Percentile ¹	20th	50th	80th	95th	
	nmol/L	Low	Moderate	Borderline High	High	Very High
LDL-P (LDL Particle Number)	1754	< 1000	1000 - 1299	1300 - 1599	1600 - 2000	> 2000


1. Reference population (5,362 men and women) not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. Atherosclerosis 2007.

❖ **Lipids**

	mg/dL	Optimal	Near or Above Optimal	Borderline High	High	Very High
LDL-C (calculated)	147	< 100	100 - 129	130 - 159	160 - 189	≥ 190

HDL-C	59	Triglycerides	115	Total Cholesterol	226
Desirable ≥ 40		Desirable < 150		Desirable < 200	

Historical Reporting



❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.



Issued or Pending
PATENTS

The NMR LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 6,518,069; 6,576,471; 6,653,140; and 7,243,030

CLIA Number 34D0655059

Specimen Number 233-174-1511-0		Patient ID		Account Number 10215230	Account Phone (678) 303-4420	Account Fax (678) 303-4420
Patient Last Name CARVER		Patient First Name LINDSEY		Account Address Flowers Medical Group Lynn Flowers MD 1950 Spectrum Circle Suite 505 Marietta, GA 30067		
Age 32	Date of Birth 03/26/1989	Sex F	Fasting YES			
Control Number B0116788491		NPI 1295088557				
Date Collected 08/21/2021	Date Entered 08/21/2021	Date and Time Reported 08/22/2021 06:15 PM ET		Physician ID & Name 12731387 - FLOWERS, L		Page Number 2 of 2

PARTICLE CONCENTRATION AND SIZE



Clinician Notes

❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

① LipoScience reference population comprises 4,588 men and women without known CVD or diabetes and not on lipid medication.

② Shalaurova I et al., Metab Syndr Relat Disord 2014; 12:422-9.

③ Mackey RH et al., Diab Care 2015; 38:628-36.